Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Zomepirac sodium inhibited the reflex hypertension caused by an injection of bradykinin into the splenic artery of anaesthetized dogs, but not that by injection of bradykinin plus PGE1. In the rat acetic acid writhing test, the potency ratio of intraperitoneal (ED50 = 0.41 microgram/kg) to intravenous (ED50 = 33.5 micrograms/kg) anti-writhing activity of zomepirac sodium was 79.2 (37.1-173), though the ratio of codeine phosphate (373 micrograms/kg, i.p., 352 micrograms/kg, i.v.) was 0.934. When equipotent doses of zomepirac sodium were administered to rats receiving intraperitoneally acetic acid, the plasma zomepirac level after i.v. administration was more than 200 times that after i.p. administration, while the peritoneal exudate zomepirac contents were nearly equal after administration by both routes. Zomepirac sodium (5 micrograms/kg) did not produce significant anti-writhing activity after intracerebroventricular administration. From these results, it was suggested that zomepirac sodium produced analgesic action through a strong blockade of the hyperalgesia in the peripheral system.
 ...
PMID:Site of analgesic action of zomepirac sodium, a potent non-narcotic analgesic in experimental animals. 668 2

Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.
 ...
PMID:Reversible nonoliguric acute renal failure associated with zomepirac therapy. 707 69